iSpecimen Inc. (NASDAQ:ISPC) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET

Company Participants

Tracy Curley - Chief Executive Officer

Benjamin Beilak - Chief Information Officer

Eric Langlois - Chief Revenue Officer

Conference Call Participants

Matt Hewitt - Craig Hallum Capital Group

Operator

Good morning, and welcome to iSpecimen First Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note that this event is being recorded.

I would now like to turn the conference over to Tracy Curley. Please go ahead.

Unidentified Company Representative

Thank you, operator. Good morning, everyone, and welcome to iSpecimen First Quarter 2023 Results Conference Call. With us on today's call is Tracy Curley, Chief Executive Officer; Benjamin Beilak, Chief Information Officer; and Eric Langlois, Chief Revenue Officer.

Before we begin, I would like to remind you that today's call contains certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities and Exchange Act of 1934 as amended, concerning future events. Words such as may, should, projects, expects, intend, plan, believes, anticipates, hopes, estimates and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are subject to numerous conditions, many of which are beyond the control of the company, including those set forth in the Risk Factors section of the company's Form 10-K for the year ended December 31, 2022, filed with the SEC. Copies of this document are available on the SEC's website at www.sec.gov. Actual results may differ materially from those expressed or implied by such forward-looking statements. The company undertakes no obligation to update these statements for revisions or changes after the date of this call, except as required by law.

Now it is my pleasure to introduce Tracy Curley, Chief Executive Officer. Tracey, please go ahead.

Tracy Curley

Good morning, everyone, and thank you for joining today's call. I will begin with a review of current business and operational activities and then discuss our financial performance for the 3 months ended March 31, 2023. We will then open the call for questions. Allow me to begin with a quick review of the Q1 2023 filing, a number of which were also touched upon during our year-end call in March. In January, I was appointed to the position of permanent CEO, and Eric Langlois was named Chief Revenue Officer. Although we have new titles, Eric and I have been with iSpecimen since 2020 and 2016, respectively. Armed with our new titles, we have been working closely with the entire iSpecimen team to execute our strategic plans and key initiatives that were identified and communicated at the end of 2022, setting the stage for an exciting and challenging 2023. Eric is leading the efforts of our recently realigned commercial team to increase our customer base and improve the overall customer experience. New responsibilities also include addressing supplier constraints as well as supporting innovation, collaboration and productivity across our lines of business, all of which are required to drive scalable and profitable growth.